Index Intelligence

· daily

S&P 500 Consumer Staples Sector SEC Filings — April 03, 2026

Across 50 filings in the USA S&P 500 Consumer Staples stream (with broader context), proxy season dominates with 20+ DEF/DEFA14A filings signaling annual meetings in May 2026, highlighting mixed 2025 performance: solid adjusted metrics (e.g., Kraft Heinz adj EPS $2.60, Mondelez >$3B FCF target) amid GAAP challenges and cocoa volatility. Period-over-period trends show selective growth (McCormick strong vote approvals, Deluxe Data Solutions +31.3% YoY) but declines in others (Elventix cash -64.4%, Print -5.7%). Capital allocation leans positive with dividends declared (Alta Equipment $0.625/DS) and redemptions (Moog 2027 notes). CMBS trusts report uniform special servicer changes for Potomac Mills (8.9%-2.1% pool weights) and Essex loans to Torchlight/KeyBank, neutral but watch for loan distress. No widespread insider trading patterns; forward-looking includes Mondelez 3-5% organic growth long-term, Relmada Phase 3 mid-2026. Portfolio-level: 3/3 Staples firms (MDLZ, KHC, MKC) show resilient adj growth vs. sector headwinds, but mixed sentiment prevails. Actionable: Buy dips in staples on FCF strength; monitor CMBS for CRE risks spilling to staples supply chains.

24 high priority 26 medium 50 total filings
· daily

S&P 500 Industrials Sector SEC Filings — April 03, 2026

Across 50 filings in the USA S&P 500 Industrials stream (with some cross-sector context), proxy season dominates with 20+ DEF/DEFA14A filings highlighting robust 2025 performance in key industrials like GE Vernova (revenue +9% YoY to $38B, backlog $150B) and ITT Inc. (revenue +8% YoY to $3.9B, FCF $555M), amid capital returns exceeding $4B combined via buybacks and doubled dividends; however, small-cap distress signals emerge with delisting notices (Twin Vee, Matinas). Period-over-period trends show 3/5 detailed industrials with double-digit revenue/earnings growth (avg +10% revenue, +50% EBITDA), but REITs like Generation Income Properties report widening net losses (-31% YoY) and equity deficits. M&A activity accelerates (ITT's $4.8B SPX FLOW deal closed Mar 2026, Aurinia acquiring Kezar Q2 2026), while forward-looking catalysts cluster in May 2026 annual meetings and Q1 earnings (e.g., SouthState Apr 23). No widespread insider selling patterns, but neutral transitions/resignations in 10+ filings signal steady governance; capital allocation tilts bullish with $10B+ buyback authorizations. Portfolio-level, 7/10 high-materiality filings bullish on orders/backlogs, positioning industrials for reacceleration despite mixed bank/health crossovers.

26 high priority 24 medium 50 total filings
· daily

S&P 500 Energy Sector SEC Filings — April 03, 2026

In a very quiet session for S&P 500 Energy with only one filing, Token Communities Ltd. (TKCM) 10-K dominates as the highest materiality event (9/10), revealing severe FY2025 operational distress with revenues crashing 85% YoY to $356,579 from $2.43M, home sales plunging 87% to $315k, gross margins contracting 98% to $18,499, and a net loss of $464k versus $1.28M profit prior year. Counterbalancing trends include total assets expanding 51% YoY to $6.04M, inventory surging 47% to $5.82M, cash jumping 142% to $62,841, and new construction in progress at $157k, signaling aggressive capacity buildup amid $157k investing cash outflow. Liabilities climbed 29% to $11.24M with a fresh $3.17M construction loan, widening the stockholders' deficit 10% to $5.20M from $4.74M, while shares outstanding held steady at 2.10B. Mixed sentiment stems from plummeting profitability versus asset/inventory expansion for potential rebound. No portfolio-level patterns emerge from the single filing, but TKCM's metrics highlight outlier distress in a sector context, with implications for turnaround potential if housing/energy-linked demand recovers, though leverage risks loom large.

1 high priority 1 total filings
· daily

Dow Jones 30 Stocks SEC Filings — April 03, 2026

Across 50 SEC filings from the USA Dow Jones 30 intelligence stream (with broader coverage including related small/mid-caps and SPACs), overarching themes include intense proxy season preparations for May 2026 annual meetings (15+ filings like GEV, BAC, Valley, EVgo), robust blue-chip growth (GE Vernova +9% YoY revenue to $38B, +213% net income to $4.9B; Bank of America +13% NI to $30.5B, +7% revenue to $113.1B), and elevated SPAC/M&A activity (12+ deals/extensions like OSRH license, Crown Reserve SPAC, ENVIRI $3.04B sale). Period-over-period trends reveal strong revenue expansion averaging ~25% YoY in reporting firms (Karman +36.6% to $471.5M, GEV +9%, BofA +7%) but mixed margins (Karman -290bps to 15.5%, NeOnc Q4 net loss +422% to $62.1M) and cash flow swings (Karman op cash -$22M vs +$26M YoY). Capital allocation favors shareholders at blue-chips (GEV dividend doubled to $2/share, buyback auth +$4B to $10B; BofA 28% TSR), while small caps face delisting risks (Twin Vee, Matinas). Portfolio-level patterns signal industrial/defense strength (record GEV $150B backlog), banking resilience, but biotech/delisting vulnerabilities; actionable now: buy blue-chip dips, avoid listing-threatened names ahead of catalysts.

33 high priority 17 medium 50 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — April 03, 2026

Across 50 filings in the USA S&P 500 Consumer Discretionary intelligence stream (though spanning broader sectors via 13Fs and trusts), dominant themes include a surge in proxy statements (15+ filings) for annual/special meetings in May-June 2026 focused on director elections, compensation votes, and auditor ratifications, signaling peak governance season. Financial trends show robust revenue/volume growth in outliers like AsiaFIN Holdings (+51.5% YoY revenue), Figure Technology (+102% YoY loan volume), and Bank of America (+13% YoY net income), but persistent margin compression (e.g., AsiaFIN -490bps gross margin) and covenant breaches (Flux Power EBITDA default). Key developments: First Tracks Biotherapeutics spin-off (Apr 20 distribution), Forian Inc. take-private at 22.6% premium (Q2 2026 close), multiple CMBS servicer switches to Torchlight, and financing expansions (e.g., Blue Owl $100M revolver). No major insider trading patterns noted (zero buys/sells detailed), limited capital allocation shifts (e.g., AFG $707M returns), and neutral sentiment overall (70% filings). Portfolio implications: Watch Consumer Discretionary proxies (YUM, Braemar) for stability amid sector volatility; alpha from spin-offs and M&A catalysts.

29 high priority 21 medium 50 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — April 03, 2026

Across 28 filings in the USA S&P 500 Healthcare stream (with broader financial context), proxy season dominates with 8+ AGMs scheduled for May 2026, highlighting governance focus amid executive transitions in biotechs (resignations, deaths, appointments). Biotech firms show cost-control measures like lease terminations (Kezar paid $1.3M fee), option repricings (Skye for 2.4M shares at $0.615), and auditor switches (Arcadia amid going concern issues), signaling cash preservation in a challenging environment. AbbVie slashed 2026 adj EPS guidance by $0.41 to $13.96-$14.16 due to $744M Q1 IPR&D expense, a major bearish signal for pharma; contrast with CVS Health's robust 2025 revenue of $402.1B and $10.6B op cash flow. Small biotechs like Elventix report deepening losses ($31k Q1, cash -64% to $890) and equity deficits, while HeartSciences faces leadership void post-COO death but reaffirms no operational disruption. No widespread insider buying/selling, limited capital returns data (American Financial returned $707M), and mortgage trusts show servicer changes without financial impacts. Portfolio trend: Neutral-to-mixed sentiment (12/28 neutral), with healthcare outliers in negative guidance/leadership risks vs positive large-cap performance; watch May catalysts for voting outcomes and earnings.

12 high priority 16 medium 28 total filings
· daily

S&P 500 Technology Sector SEC Filings — April 02, 2026

The 22 filings from USA S&P 500 Technology stream (April 2, 2026) are dominated by 10 proxy-related documents (DEF 14A/DEFA14A) for May 2026 AGMs, reflecting routine governance with neutral sentiment across NCS Multistage, Iridium, Radian Group, Apple Hospitality REIT, and Community Health Systems; no major disputes or declines noted. Executive transitions in 5 companies (Optimum Communications EVP demotion/retirement with $3.6M payout, Zoom COO resignation May 8, Broadcom CFO retirement Jun 12 with Alphabet CAO successor, Esquire director health-related exit, CareView ongoing debt amendments) are neutral, signaling stable leadership changes without disagreements. Positive financing and operational highlights include ISQ Open Infrastructure's $28.3M unregistered equity raise and $0.34/share distribution (May 5), Immunic's Phase 3 enrollment completion (2,221 patients, topline end-2026), CHS's 2025 net income turnaround to $509M from -$516M loss despite -1.2% YoY revenue to $12.5B, $3.3B debt reduction, and Aditxt Nasdaq compliance confirmation ($4M equity). Apple Hospitality reported 2025 buybacks of 5M shares, hotel portfolio optimization across 84 markets. Portfolio-level trends show sparse but improving financials (e.g., CHS EBITDA margin flat 12.2%, positive FCF), capital returns via buybacks/debt paydown/distributions, and catalysts like biotech data; implications favor monitoring leadership stability and May events amid low volatility.

12 high priority 10 medium 22 total filings
· daily

Nasdaq 100 Stocks SEC Filings — April 02, 2026

Across 26 NASDAQ-100 related SEC filings dated April 2, 2026, dominant themes include a surge in proxy statements (10+ DEF/DEFA14A) signaling the onset of 2026 proxy season with clustered annual meetings in May, alongside notable executive transitions at tech leaders like Zoom (COO resignation), Alphabet (controller resignation), Broadcom (CFO retirement with Alphabet alum appointment), and Booking Holdings (new CAO). Financial highlights reveal mixed performance: Community Health Systems achieved a dramatic net income turnaround to +$509M from -$516M loss YoY despite -1.2% revenue decline, Trilogy Metals saw Q1 FY2026 loss double to $7.1M YoY amid higher expenses, Tesla reported flat +1% YoY Q1 vehicle deliveries at 358K, and Starbucks closed a positive China JV ceding 60% control for liquidity. Positive catalysts include Immunic's Phase 3 enrollment completion with topline data by end-2026, Booking's 25-for-1 stock split, and Aditxt's Nasdaq compliance resolution. Portfolio-level trends show neutral-to-positive sentiment (8 positive, 12 neutral, 4 mixed, 2 bearish implied), with healthcare/mining outliers in deteriorating losses/revenues but debt reductions/buybacks signaling capital discipline; no broad margin compression evident but limited QoQ/YOY data (e.g., Trilogy cash -7.4% QoQ, CYH EBITDA margin flat 12.2%). Implications favor monitoring May proxy votes for equity plans/governance and Q1 earnings catalysts like Tesla's April 22 webcast for deeper financials.

15 high priority 11 medium 26 total filings
· daily

S&P 500 Financials Sector SEC Filings — April 02, 2026

Across 50 SEC filings from the USA S&P 500 Financials stream (with cross-sector exposure including REITs, financial data providers, pharma/mining outliers), sentiment is mixed with 12 positive, 14 mixed, and 10 negative summaries; period-over-period trends reveal revenue growth averaging +18% YoY in outperformers like Pharming (+26.6% to $376M), Dynaresource (+25.7% to $58M), and FactSet (+7% to $611M Q), but sharp declines in underperformers like Airsculpt (-15.8% FY to $152M), LightInTheBox (-12.2% to $224M), and Lindsay (-16% Q2 to $158M). Capital allocation emphasizes buybacks (News Corp $1B program, FactSet $303M YTD, Lindsay $25M Q2, Oceaneering $40M) and dividends (Burford 6.25¢ final), signaling shareholder returns amid volatility; M&A/SPAC activity is robust with accretive deals like Kodiak's $587M DPS acquisition (+395MW capacity) and Crown Reserve's $1B EV Carvix combo ($80M PIPE). Forward-looking catalysts cluster in May 2026 AGMs (20+ filings, e.g., Sylvamo May15, Burford May13) and guidance reaffirms (ESAB, Sally Beauty FY26); debt actions improve liquidity (Terra exchange to 2029 notes, Transocean $358M retire/$0.75B 2026 plan, CareView maturity to Jun30). Portfolio implications: overweight accretive M&A/REIT restructurings, underweight going concerns (Mannatech, Algorhythm); sector shows resilience in financial metrics (e.g., FactSet op CF +28%) despite broader declines.

28 high priority 22 medium 50 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — April 02, 2026

Across 50 filings from the USA S&P 500 Consumer Staples intelligence stream (though diverse sectors represented), proxy statements dominate (over 60%), signaling the onset of 2026 proxy season with annual meetings clustered in May-June 2026, emphasizing governance, director elections, auditor ratifications, and say-on-pay votes. Positive outliers include accretive M&A (Kodiak's $587M acquisition adding 395MW capacity, immediately EPS/DCF accretive), record performances (Morgan Stanley's $70.6B 2025 revenues, $10.21 EPS, 21.6% ROTCE; BlackRock ESG's 86% cumulative return since 2023 vs. 56% benchmark), and capital optimization (CVGI's $16M sale-leaseback delevering facility). Limited period-over-period data shows bullish trends like Cleveland-Cliffs' 43% safety incident reduction since 2020 and Diamond Hill's $25.9B AUM (led by Consumer Staples like Costco at $57M). No widespread margin compression or revenue declines; neutral sentiment prevails (70% of filings) with positive M&A/capital raises (10%). Consumer Staples exposure indirect via 13F top holding Costco ($57M, 57k shares). Implications: Low sector distress, focus on governance catalysts and M&A for alpha; monitor May meetings for votes.

27 high priority 23 medium 50 total filings
· daily

S&P 500 Industrials Sector SEC Filings — April 02, 2026

The 50 filings from USA S&P 500 Industrials stream reveal a dominant proxy season theme with 25+ DEF 14A/DEFA14A filings for May-June 2026 annual meetings, emphasizing strong 2025 performances, board elections, equity plan approvals, and auditor ratifications amid positive sentiments in 70% of cases. Period-over-period trends show robust growth in select industrials like Acuity Inc. (H1 sales +12.3% YoY to $2.2B, net income +18% to $217M) and transportation (Norfolk Southern HQ lease renewal $499M over 5 years), contrasted by losses in Pharvaris (+31% YoY net loss to €176M) and Pheton (net loss ballooning to $5.1M). Capital allocation shines with Acuity's $106M buybacks, 18% dividend hike, Phillips 66's $3.1B returns (>50% cash flow), and debt reductions (Acuity LT debt -22% to $697M). M&A/integration activity (Associated Banc merger, Bed Bath TBHC acquisition at 0.1993x ratio) and defense catalysts (Kratos share authorization +25% to 245M, Cocrystal FDA Fast Track) signal conviction, while cash declines (Acuity -36% to $273M, Pheton -76%) flag liquidity risks. Forward-looking catalysts cluster in Q2 2026 meetings and Sept PDUFA, positioning industrials for governance-driven upside amid mixed sentiment (positive in 40%, neutral 40%). Portfolio-level, 6/10 financial reporters show avg +18% revenue growth but variable margins (+20% op profit Acuity vs compressions elsewhere), implying selective buying in growth outliers.

27 high priority 23 medium 50 total filings
· daily

S&P 500 Energy Sector SEC Filings — April 02, 2026

The S&P 500 Energy stream filings highlight proxy season convergence with four companies (Phillips 66, Dorchester Minerals, Kinder Morgan) scheduling 2026 Annual Meetings for May 13, emphasizing governance, director elections, compensation votes, and auditor ratifications amid record dates in March. Devon Energy advances its transformative merger with Coterra Energy, clearing HSR antitrust review on April 1, 2026, positioning for Q2 close and enhanced scale in oil/gas production. Phillips 66 showcases robust 2025 performance with record refining yields, NGL volumes, crude utilization, $3.1B shareholder returns (over 50% of net operating cash flow ex-WC), 10% dividend hike, strategic acquisitions (EPIC NGL/Coastal Bend, WRB Refining), and debt reduction target to $17B by 2027. Lion Copper & Gold reports FY2025 net income swing to $4.4M profit from $4.7M loss, driven by $26.4M deconsolidation gain, but operating loss ballooned to $16.7M from $3.8M on higher G&A (+101% YoY) and share-based comp (+476% YoY), with cash plummeting 70% YoY to $2.4M and negative operating cash flow of $13.2M vs prior positive. Kinder Morgan and Dorchester filings are routine proxies with neutral sentiment, low materiality. Portfolio-level trends show capital returns strength at Phillips contrasting Lion's cash burn; M&A momentum via Devon/Phillips deals signals consolidation. Implications: Near-term catalysts in shareholder votes and merger close favor bullish positioning in Devon/Phillips, caution on Lion liquidity.

4 high priority 4 medium 8 total filings
· daily

Dow Jones 30 Stocks SEC Filings — April 02, 2026

Across 50 SEC filings from the USA Dow Jones 30 intelligence stream (April 2, 2026), proxy statements dominate (over 25 DEF/DEFA14A filings) signaling peak annual meeting season in May 2026, with neutral sentiment on governance but positive undertones in board refreshes and comp approvals. Key period trends show selective revenue acceleration (e.g., Pharming +26.6% YoY to $376M, Venu sales +62% YoY to $126M) amid flat/declining cases (Venu rev flat, Lovesac internet -2%, other -37%), with margin pressures in retail (Lovesac -210 bps to 56.4%) offset by profitability swings (Pharming to +$26M op profit). M&A activity surges bullish (Kodiak accretive $587M deal +395MW capacity, Soluna $53M wind farm, Clear Channel $2.43/share buyout), while trusts/BDCs face wind-downs (MV Oil terminates June 30, Nuveen liquidation). Biotech mixed with expansions (Roivant Phase 3 trials) but failures (Immunovant TED trials miss). Capital allocation leans defensive (Lovesac $6M buybacks, dividends in Solstice), no broad insider trading patterns but leadership changes signal transitions (Sally Beauty CFO appt, Fiserv CEO). Portfolio implications: Favor M&A targets and revenue growers for near-term alpha, monitor May catalysts and trust liquidations for volatility.

28 high priority 22 medium 50 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — April 02, 2026

The 50 filings reveal a heavy focus on proxy season preparations for May 2026 AGMs across diverse issuers, including director elections, say-on-pay approvals, auditor ratifications, and equity plan expansions, signaling governance stability amid S&P 500 Consumer Discretionary peers. Period-over-period trends show mixed results: revenue growth in 4/50 (FactSet +7% YoY to $611M Q, BBB Foods +36.1% YoY to Ps78B, FreeCast gross profit +77% YoY despite revenue -4%), but profitability challenges (FactSet NI -8% YoY, BBB operating loss widened 150.8% YoY, Ashford pro forma revenue -1.6% but loss improved). Capital allocation leans shareholder-friendly with FactSet $303M buybacks (OCF +28% YoY), Burford 6.25¢ dividend (June payable), and Booking 25:1 stock split effective April 2. Leadership churn prominent (12/50 appointments/retirements, e.g., Booking CAO, Oportun interim CEOs), with financings (Fibro $3M offering, Caris $400M loan) and M&A (Ashford $24.8M hotel sale net, Marine Products merger pro forma EPS $0.40). No widespread insider trading patterns, but positive sentiments in 10/50 (e.g., board additions). Sector implications: monitor May catalysts for governance risks, favor revenue growers like FactSet amid margin pressures; portfolio trend of improving cash flows (FreeCast ops burn -22% YoY) supports buybacks/dividends over reinvestment.

26 high priority 24 medium 50 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — April 02, 2026

Across 50 filings in the USA S&P 500 Healthcare intelligence stream (with broader financial and sector crossovers), dominant themes include a heavy proxy season with 15+ DEF 14A/DEFA14A filings scheduling virtual annual meetings in May 2026 for director elections, auditor ratifications, and equity plan approvals; frequent C-level transitions (9 CFO/COO/CEO changes or appointments); and financing maneuvers like new $400M+ term loans and maturity extensions. Period-over-period trends show selective revenue acceleration (e.g., Vertex $12B total 2025 revenues driven by CF franchise; BD Q1 FY2026 revenues +3.5% YoY to $4.486B, GAAP op income +66% to $468M) amid mixed adjusted metrics (BD adj EPS -10.1% YoY) and comp variances (ENB PEO +3% YoY to $604K, NEOs -39% to $335K). Healthcare-specific highlights feature biotech trial catalysts (Roivant brepocitinib PDUFA Q3 2026 despite Immunovant Phase 3 failures) and device/financing positives (Caris $400M term loan, BD momentum in CASGEVY/JOURNAVX). Capital allocation leans toward equity incentives and buybacks ($1B News Corp program), with neutral-to-positive sentiment (60%+ positive/neutral). Portfolio implications: monitor May proxy outcomes for governance shifts and Q2/Q3 biotech catalysts amid leadership churn signaling potential strategic pivots.

30 high priority 20 medium 50 total filings
· daily

S&P 500 Technology Sector SEC Filings — April 01, 2026

Across the 15 filings in the USA S&P 500 Technology stream (with broader exposure via context), dominant themes include M&A completions and amendments (CWBC merger, CYH asset sale, LUNR acquisition), financing activities (NOW credit agreement, Cottonwood/Lafayette stock raises, MU tender offers), and mixed financial results highlighted by MLP's 68% YoY revenue growth offset by 43% wider net loss. Period-over-period trends show revenue surges in select areas (MLP leasing +1,000% YoY, land sales +68% YoY) but declines elsewhere (CYH pro forma revenues -327M, MLP unidentified segment -41% YoY), with no dominant margin compression but operational losses persisting. Tech-specific signals are positive: ServiceNow's credit facility enhances liquidity, Micron's debt tender manages liabilities, Intuitive Machines advances $800M acquisition integration. Portfolio-level patterns reveal 4/15 filings with strong YoY revenue growth (>50%), 5 with net loss expansions, and forward catalysts like Immunic's Phase 3 data by end-2026. Critical implications: M&A scale-ups boost assets (CWBC to $5B), but pro forma declines flag revenue risks; actionable now for post-deal trading opportunities amid neutral insider/institutional patterns.

6 high priority 9 medium 15 total filings
· daily

Nasdaq 100 Stocks SEC Filings — April 01, 2026

Across 18 NASDAQ-100 related SEC filings from April 1, 2026, dominant themes include transformative M&A activity (CWBC merger, KDP JDE Peet's acquisition, LUNR $800M Lanteris buy, CYH $459M asset sale) signaling consolidation in banking, beverages, space, and healthcare, with combined entities boasting $5B+ assets or $16B+ revenues. Period-over-period trends show revenue growth in land development (MLP +68% YoY to $19.5M, leasing +1000% YoY to $5.8M) and financing inflows (FF +100% YoY cash to $161.4M), but persistent operating losses (FF $331M FY2025, MLP net loss +43% to $10.6M) and pro forma declines (CYH revenues - $327M). Positive catalysts include Nasdaq compliance regains (Immunic), product validations (AITX), and equity turnarounds (FF stockholders' equity +$7.7M from negative), while neutral proxy filings (UCBI, Intellicheck) and institutional ownership (WMG 13G 5.1%) indicate routine governance. Portfolio-level patterns reveal mixed sentiment (7 positive/mixed growth, 9 neutral), with capital raises via stock sales (Cottonwood $3.6M) and debt optimization supporting turnarounds amid Nasdaq bid price pressures (FF notice). Market implications favor M&A beneficiaries for near-term synergies but flag liquidity risks in loss-making firms.

8 high priority 10 medium 18 total filings
· daily

S&P 500 Financials Sector SEC Filings — April 01, 2026

Across 50 SEC filings from the USA S&P 500 Financials stream (broadly including banks, funds, REITs, and related sectors), overarching themes reveal robust M&A/divestiture activity (10+ deals like CWBC merger, CHS $459M sale, Duke $2.48B divestiture), mixed financial performance with bifurcation—revenue grew +17-52% YoY in 9 firms (avg +28%) but plunged -25-78% in 8 (avg -52%), and margin expansions (+900bps in AIDX, +140bps ASE) offsetting compressions. Capital allocation favors returns ($766M WY cash to SH, Cal-Maine $24.3M buyback/$0.36 div), but small caps/biotechs show dilution risks via warrants/placements (e.g., LABT $7.5M pref, Cadrenal inducement). Forward-looking catalysts include growth targets (WY $1.5B EBITDA by 2030, Lamb Weston raised FY26 guidance $6.45-6.55B sales), fund conversions (TCW Jun 2026), and AGMs (WY May 15). Sparse insider data shows no major sales/buys, but mgmt conviction via promotions/div hikes. Portfolio-level: Financials/funds stable (Nuveen $120M Q1 subs), while cyclicals/commodities volatile; actionable now—favor M&A beneficiaries amid reg risks (LFTD hemp bans).

32 high priority 18 medium 50 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — April 01, 2026

Across 50 SEC filings from the S&P 500 Consumer Staples stream (April 1, 2026), dominant themes include proxy season acceleration with 20+ DEF 14A/DEFA14A filings for May 2026 annual meetings emphasizing director elections, say-on-pay, and auditor ratifications, alongside mixed Q3/FY2025 results showing organic sales resilience (e.g., Conagra +2.4% organic vs -1.9% reported YoY) but widespread margin compression and EBITDA declines in staples like Lamb Weston (-27% adj EBITDA despite +3% sales YoY). M&A activity surges with Keurig Dr Pepper's 96.22% acquisition of JDE Peet’s (EUR 9.9B 2025 sales) for a YE2026 coffee spin-off and Cyclerion's dilutive merger (1.5% ownership retention). Period-over-period trends reveal revenue volatility (Safe & Green +3,900% YoY to $8.2M but loss widened to $16M; Rocky Mountains -50.5% Q1 YoY), improving losses in biotech (Monopar -12% YoY), and capital returns via dividends (Armour $0.24/share, Lamb $0.38) and buybacks (IPG $50M, DFIN $172M record). Forward-looking signals mixed: Lamb Weston raised FY2026 sales/EBITDA midpoints, Conagra narrowed to margin high-end ~11.0-11.5%, with catalysts like BioXcel FDA PDUFA Nov 14, 2026. Leadership churn prominent (6+ CFO/GC changes), no widespread insider selling/buying patterns noted. Portfolio implications: Favor M&A/transforming staples (KDP) over margin-squeezed peers; monitor May proxies for governance shifts amid sector resilience via organic growth offsetting inflation.

24 high priority 26 medium 50 total filings
· daily

S&P 500 Industrials Sector SEC Filings — April 01, 2026

Across 50 SEC filings from S&P 500 Industrials and related entities on April 1, 2026, sentiment is predominantly mixed (14/50), with positive tones in M&A completions, dividend declarations, and strong FY2025 results (e.g., L3Harris $21.9B revenue + backlog growth), offset by revenue declines (avg -10% YoY in 7 firms like Innate Pharma -78%, Bassett -2.2%) and widening losses (e.g., Safe & Green net loss +79% to $16M). Period-over-period trends show revenue growth in 6/20 quantifiable filers (e.g., URBN +11.1%, Enphase $1.5B), margin expansions in outperformers (L3Harris + to 15.8%, URBN + to 36%), but compression elsewhere (Bassett -80bps); capital allocation favors dividends (5 declarations, e.g., Global Net Lease $0.19/share) and buybacks (URBN $177M, IPG $50M). M&A activity peaks with Community West-USFO merger ($185M), property dispositions boosting liquidity (Medalist cash to $19M), and capital raises (Charlotte's Web $75M BAT commitment). Insider activity sparse, but management conviction seen in approvals (Golden Entertainment 98% MTA vote). Forward catalysts cluster in May-Jun 2026 proxy/AGM season (L3Harris May 11, Enphase May 13), signaling portfolio rotation opportunities amid volatile direct listings (Lakewood-Amedex) and delisting risks (Safe & Green, Faraday). Overall, industrials exhibit resilient capital returns but bifurcated growth, favoring selective longs in defense/energy storage over cyclicals.

25 high priority 25 medium 50 total filings